𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of the combination therapy Pilogel®/β-blocker: Interim results

✍ Scribed by S. Maas; F. E. Ros; LJ. Heer; R. J. W. Keizer

Publisher
Springer-Verlag
Year
1989
Tongue
English
Weight
335 KB
Volume
72
Category
Article
ISSN
0012-4486

No coin nor oath required. For personal study only.

✦ Synopsis

The interim results of a multicentered clinical trial with the combination therapy Pilogel| t-blocker (twice daily) in patients with primary open angle glaucoma or ocular hypertension are discussed. Six patients were treated with Pilogel | and a topical t-blocker for one month. Four out of six patients responded well to the combination therapy. Most patients experienced some difficulty in applying the gel and their eyelids stuck together on awakening. In two patients a superficial punctate keratitis was observed. We found an average decrease in intra-ocular pressure (IOP) of 22.5 % 22.5 hours after Pilogel | administration, but there was some tendency towards higher evening values compared to morning values. In view of the appearance of a corneal haze as described by Johnson et al. during long-term treatment, longer follow-up is necessary.

📜 SIMILAR VOLUMES

Efficacy and safety of certolizumab pego
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey
✍ Alain M. Schoepfer; Stephan R. Vavricka; Janek Binek; Christian Felley; Martin G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Background: Switzerland was the first country to approve certolizumab pegol (Cimzia, CZP) for the treatment of patients with moderate to severe Crohn's disease (CD) in September 2007. This phase IV study aimed to evaluate the efficacy and safety of CZP in a Swiss multicenter cohort of practice-based

Anastrozole alone or in combination with
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d